Replies to post #777997 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

You are reiterating what I already stated... Duh.
Also, I already posted my email text a while ago, when I got it.
I have all the original emails and mega data. ..
I never said rejection or approval, I said it seems to be held up for one reason or several reasons.
Again, your questions should be directed to NWBO, that is the latest advice I got from Variations.
I have no intention of contacting the company - I have in the past and was less than impressed with the misdirection,, untruths, unprofessionalism and frankly, unsolicited investment advice. To be totally honest. I'll leave it at that.
Everyone should do their own due diligence, and this company should be more candid with shareholders. MHRA does NOT restrict sponsors from corresponding with their shareholders, that was a management choice by NWBO.

[sentiment_stocks]

I'm wondering if perhaps we're reading SI-87 in error. It's the "specials" wording that makes me wonder if SI-87 patient specific labeling is meant to enable treatments such as DCVax-L to be made and given to patients with other cancer indications, like breast or lung, etc.

Meanwhile, the MAA process continues at what ever stage it's at, but when approved, SI-87 will not apply to DCVax-L for GBM or recurrent GBM, as the MA will cover it.

Thoughts?